Bromhexine
Based on 4 publication(s) in Google Scholar
Bromhexine is a potent expectorant. Bromhexine increase mucociliary clearance and reduces cough. Bromhexine can be used in study various respiratory diseases.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.59%
- No. CAS: 3572-43-8
- Fòrmula: C14H20Br2N2
- Peso molecular:376.13
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Bromhexine
MoreVer todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
Descripciòn
Ensayo clínico
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 3572-43-8
-
Appearance Solid
-
Peso molecular 376.13
-
Fòrmula C14H20Br2N2
-
Color White to off-white
-
SMILES
BrC1=CC(Br)=CC(CN(C)C2CCCCC2)=C1N
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Biochem Pharmacol
ALOX5 Promotes Autophagy-dependent Ferroptosis by Activating the AMPK/mTOR Pathway in Melanoma. [Abstract]2023 Jun:212:115554. PMID: 37080437 -
Int Immunopharmacol
A natural product, Piperlongumine (PL), increases tumor cells sensitivity to NK cell killing. [Abstract]2021 Jul:96:107658. PMID: 33887610 -
BMJ Open Respir Res
Respiratory syncytial virus-induced SIGLEC1 upregulation inhibits macrophage autophagy and facilitates inflammatory mediator secretion. [Abstract]2026 Apr 20;13(1):e003586. PMID: 42009498 -
FEBS Lett
Bromhexine elevates REP2 expression to stimulate secretion from human primary conjunctiva fornix epithelial cells. [Abstract]2020 Jan;594(1):153-160. PMID: 31365127
Protocolo
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Pureza y Documentación
-
Ficha de datos (268 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)